Welcome to our dedicated page for Petvivo Holdings SEC filings (Ticker: PETVW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for PetVivo Holdings, Inc. (PETVW warrants, PETV common stock) provides direct access to the company’s official regulatory disclosures. These documents, filed with the U.S. Securities and Exchange Commission, offer detailed information about corporate events, governance changes, investor communications and financial presentations that are relevant to understanding the business underlying the PETVW warrants.
Recent Form 8-K filings illustrate how PetVivo reports material events. For example, one Form 8-K describes the appointment of an independent director to the board and the expansion of the board’s size, while another notes the resignation of a director and a corresponding reduction in the number of board seats. Other 8-K filings furnish investor presentations under Regulation FD, making slide decks and related materials part of the public record without treating them as filed for liability purposes.
Through its filings, PetVivo identifies itself as a Nevada corporation with a specific Commission File Number and employer identification number, and it provides its corporate telephone contact. These documents complement the company’s news releases that describe its focus on manufacturing, commercialization and licensing of veterinary medical devices and therapeutics for companion animals and horses, as well as its AI initiatives via PetVivo AI, Inc. and the PetVivo.ai platform.
On Stock Titan, this filings page is updated as new PetVivo documents are posted to the SEC’s EDGAR system, enabling users to review 8-Ks, investor presentations and other reports in one place. AI-powered tools can help summarize key points from lengthy filings, highlight sections related to board composition, strategic agreements or investor communications, and make it easier to connect these disclosures with the performance of the underlying PETVW warrants.
PetVivo Holdings (PETV) reported an insider transaction on Form 4. Chief Financial Officer Garry Lowenthal received 75,000 shares of restricted common stock on 10/23/2025 at a reported price of $1.27 per share. The grant was issued to a corporation owned by him as compensation for past performance. After this grant, he beneficially owns 667,967 shares, held indirectly through the corporation.
PetVivo Holdings (PETV) reported an insider transaction on a Form 4. CEO and Director John Lai acquired 75,000 shares of common stock on 10/23/2025 at $1.27 per share. The filing states the shares were a grant of restricted common stock to a corporation he owns, as compensation for past performance by converting a past accrued bonus into common stock.
After the transaction, Lai beneficially owned 2,095,710 shares, held indirectly through the corporation.
PetVivo Holdings (PETV) reported an insider equity award. Director Diane Levitan acquired 12,500 shares of restricted common stock at $1.28 on 10/10/2025. The award is part of an aggregate annual grant of 50,000 shares for Board service, vesting in four equal installments of 12,500 at the beginning of each quarter.
Following this transaction, Levitan beneficially owns 56,489 shares, held directly.
PetVivo Holdings (PETV) director reported multiple stock grants. On 10/01/2025, the director acquired 14,935 shares of restricted common stock at $1.19 as compensation for prior consulting services. On 10/10/2025, additional restricted stock grants were recorded: 12,500 shares at $1.28 for quarterly Board service vesting, 50,000 shares at $1.28 tied to a warrant exercise with a $25,000 payment to the company, and 100,000 shares at $1.28 tied to a warrant exercise with a $50,000 payment to the company. Following these transactions, beneficial ownership stood at 311,807 shares, held directly.
PetVivo Holdings (PETV) reported a Form 4 for director Robert Rudelius. On 10/10/2025, he acquired 12,500 shares of common stock at $1.28 as part of an annual 50,000 restricted-share board compensation grant that vests in four equal quarterly installments. Following the transaction, he beneficially owned 314,369 shares directly and 21,000 shares indirectly via a corporation.
PetVivo Holdings (PETV) reported a Form 4 showing Director Joseph Jasper acquired 12,500 restricted common shares at $1.28 on 10/10/2025. The transaction reflects the first quarterly vesting from an annual board compensation grant of 50,000 shares, vesting in four equal installments of 12,500 each.
Following the transaction, Jasper beneficially owned 100,159 shares directly, plus 2,000 shares indirectly held by his spouse.
PetVivo Holdings (PETV) disclosed a Form 4 for a director on 10/10/2025, reporting the acquisition of 12,500 shares of common stock at $1.28 per share. Following the transaction, the director beneficially owns 73,661 shares directly.
The filing notes this is part of an aggregate annual grant of 50,000 restricted shares for Board service, vesting in four equal installments of 12,500 shares at the beginning of each quarter.
PetVivo Holdings, Inc. reporting person John Lai, who serves as Chief Executive Officer and a director, reported a non‑derivative acquisition on 09/18/2025. The filing shows a grant of 84,375 shares of common stock at a price of $0.76 to a corporation owned by the reporting person as compensation for past performance, reflecting conversion of a past accrued bonus into common stock. Following the transaction, the reporting person (indirectly) beneficially owned 2,020,710 shares. The Form 4 is signed by John Lai on 09/22/2025. The filing indicates the award was issued as compensation rather than a market purchase.
Garry Lowenthal, Chief Financial Officer of PetVivo Holdings, Inc., received a grant of restricted common stock on 09/18/2025 as compensation for past performance. The grant consisted of 79,375 shares at a stated price of $0.76 and was issued to a corporation owned by Mr. Lowenthal. After the reported transaction, the reporting persons indirect beneficial ownership totaled 592,967 shares. The Form 4 indicates this was a non-derivative award recorded as an acquisition and identifies the grant as compensation rather than a market purchase.